Related Experiment Videos
Iopamidol 150. A low iodine content non-ionic water-soluble contrast medium for CT myelocisternography
A Beltramello1, M Leonardi, E Biasizzo
1Department of Neuroradiology, Borgo Trento Hospital, Verona, Italy.
Abstract:
Results of a clinical trial in CT myelocisternography performed with a new reduced concentration of iopamidol (150 mg I/ml) are reported. This compound is characterized by very low osmolality and osmotic pressure close to those of blood and CSF. Thirty patients were examined. Before, during and after the procedure pulse rate and blood pressure were recorded, EEG was taken and neurologic examination performed. After the examination no alteration in these parameters was recorded. The demonstration of the subarachnoid space and related structures was invariably adequate for diagnosis. In no case was a repeat study using a higher concentration of contrast medium needed. Mild reactions occurred only in three patients (10%). The authors conclude that iopamidol 150, owing to its safety and good imaging capacity, is useful in CT imaging of the subarachnoid space.
Insights
A new, low-concentration iopamidol (150 mg I/ml) contrast agent proved safe and effective for CT myelocisternography. This study found it provided adequate imaging of the subarachnoid space with minimal patient reactions.
Area of Science:
- Neuroradiology
- Diagnostic Imaging
- Pharmacology
Background:
- CT myelocisternography is a key diagnostic tool for subarachnoid space evaluation.
- Traditional contrast agents can have high osmolality, potentially causing adverse effects.
- Iopamidol 150 mg I/ml offers reduced osmolality, mimicking physiological fluid properties.
Purpose of the Study:
- To evaluate the safety and diagnostic efficacy of a new reduced concentration of iopamidol (150 mg I/ml) in CT myelocisternography.
- To assess the impact of iopamidol 150 on patient physiological parameters during the procedure.
Main Methods:
- A clinical trial involving 30 patients undergoing CT myelocisternography with iopamidol 150 mg I/ml.
- Monitoring of pulse rate, blood pressure, EEG, and neurological status before, during, and after the procedure.
- Assessment of image quality for subarachnoid space and related structures demonstration.
Main Results:
- No significant alterations in recorded physiological parameters (pulse, blood pressure, EEG, neurological status) were observed post-procedure.
- Consistently adequate diagnostic imaging of the subarachnoid space was achieved in all patients.
- Only mild adverse reactions (10% incidence) were reported, with no need for repeat studies.
Conclusions:
- Iopamidol 150 mg I/ml is a safe and effective contrast agent for CT imaging of the subarachnoid space.
- Its low osmolality and osmotic pressure profile contribute to patient safety and procedural comfort.
- The agent provides excellent diagnostic imaging capabilities, reducing the need for higher concentrations or repeat examinations.